Filing Flows › Comparisons › AZN vs ABT
AstraZeneca vs Abbott Laboratories: AZN and ABT compared
AstraZeneca is the larger company: $14.5B of revenue in its latest quarter (Q2 2025) against $13.0B for Abbott Laboratories (Q3 2026). Abbott Laboratories is growing faster (+14% against +12% a year earlier). AstraZeneca is more profitable, with an operating margin of 24.3% against 10.4%.
Where the money goes: AZN and ABT
AstraZeneca (AZN) · Q2 2025
AstraZeneca, Q2 2025: revenue $14.5B (+12% year over year), operating margin 24.3%, net earnings $2.4B. The chart follows the revenue to costs, profit and cash.
Abbott Laboratories (ABT) · Q3 2026
Abbott Laboratories, Q3 2026: revenue $13.0B (+14% year over year), operating margin 10.4%, net earnings $920M, operating cash flow $1.7B. The chart follows the revenue to costs, profit and cash.
| AstraZeneca (AZN) | Abbott Laboratories (ABT) | |
|---|---|---|
| Latest quarter | Q2 2025 | Q3 2026 |
| Revenue | $14.5B | $13.0B |
| Revenue growth, Y/Y | +12% | +14% |
| Gross margin | 82.9% | — |
| Operating margin | 24.3% | 10.4% |
| Net earnings | $2.4B | $920M |
| Net margin | 16.9% | 7.1% |
| Operating cash flow | — | $1.7B |
| Free cash flow | — | $1.2B |
| Market value | $289.1B | $197.4B |
| P/E | 28.3× | 42.4× |
| Analysts’ mean target | $208.07 | $118.52 |
Where the revenue comes from
AstraZeneca
- Product Revenue: $14.4B (100%)
- Collaboration Revenue: $8.0M (0%)
Questions
Which is bigger, AstraZeneca or Abbott Laboratories?
AstraZeneca is the larger company: $14.5B of revenue in its latest quarter (Q2 2025) against $13.0B for Abbott Laboratories (Q3 2026).
Is AstraZeneca or Abbott Laboratories growing faster?
Abbott Laboratories is growing faster (+14% against +12% a year earlier).
Which is more profitable, AstraZeneca or Abbott Laboratories?
AstraZeneca is more profitable, with an operating margin of 24.3% against 10.4%.
More: AstraZeneca earnings · how AstraZeneca makes money · Abbott Laboratories earnings · how Abbott Laboratories makes money
From the companies' latest 10-Q, 10-K or earnings release (6-K filed Jul 29, 2025; 10-Q filed Nov 4, 2026). Fiscal quarters can end on different dates. Not investment advice.